Lansforsakringar Fondforvaltning’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-54,968	Closed	-$2.98M	–	562
2025 Q3	$2.98M	Hold	54,968	–	–	0.02%	464
2025 Q2	$3.02M	Sell	54,968 -8,098	-13%	-$477K	0.02%	462
2025 Q1	$4.46M	Sell	63,066 -3,370	-5%	-$227K	0.03%	411
2024 Q4	$4.37M	Buy	+66,436	New	+$4.45M	0.02%	423

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Lansforsakringar Fondforvaltning's BMRN Position: Q4 2025 in Review

Lansforsakringar Fondforvaltning sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 54,968 shares — an estimated $2.98M sold.

Lansforsakringar Fondforvaltning first reported a position in BMRN in Q4 2024 and held it in 4 quarters. The position peaked at $4.46M in Q1 2025. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Lansforsakringar Fondforvaltning reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Lansforsakringar Fondforvaltning sold 54,968 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $2.98M.
Lansforsakringar Fondforvaltning first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Lansforsakringar Fondforvaltning's BioMarin Pharmaceuticals position peaked at $4.46M in Q1 2025.
540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q4 2025, filed 12 Feb 2026.